Fully Optimised Aptamers

Introducing OptimersTM
3rd October 2018
 
Proprietary process with validated improvement in delivery and performance

OptimersTM in 12 weeks
Aptamer Group is pleased to announce availability of  OptimersTM – the new standard for our custom development services.

Aptamer Group is dedicated to continually improve its service offerings to identify the best reagent(s) from within our vast aptamer libraries in the […]

Portable Aptamer Based Sensor for Toxin Detection

9th August 2018 
Aptamers continue to demonstrate advantages in platforms and applications which require specific detection of small molecule targets.
There has been a growth in the use of point of care devices across a range of applications and assay types due to a need for rapid and reliable analysis (Vashist 2017). Aptamers are perfectly suited for […]

Aptamer Group Secures $2.2m Series A Investment

Arron Tolley, CEO – I’m delighted to announce that Aptamer Group Ltd, has recently closed its Series A investment round; attracting international interest and securing $2.2m of funding from overseas investors, to support its pioneering aptamer development pipeline.

Aptamer technology is rapidly evolving and will continue to have a significant impact on the life sciences market […]

Aptamers excel as binding reagents in ELISA replacement assays for antibiotics in complex media such as plasma, milk and others

18th May 2018.

Traditionally small molecules, such as antibiotics, have been difficult targets for ELISA development. Aptamer Group has selected aptamers that bind to small molecules, previously inaccessible to other binding technologies. Utilising our state-of-the-art automation and parallel processing techniques, we can select high affinity and highly specific aptamers against small molecule targets, in solution. These […]